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Superior Suppressive Capacity of Skin Tregs
Compared with Lung Tregs in a Model of
Epicutaneous Priming
Subhashree Mahapatra1,4, Melanie Albrecht1,4, Abdul M. Baru2, Tim Sparwasser2, Christina Herrick3 and
Anna M. Dittrich1
We have previously shown that T helper type 2 (Th2)-polarized airway inﬂammation can facilitate priming to new
antigens in the lungs, which we called “collateral priming”. To investigate whether allergic skin inﬂammation can
also facilitate priming toward new antigens, we developed an allergic skin inﬂammation model based on an allergic
lung inﬂammation model. Mice were sensitized intraperitoneally toward the primary antigen, ovalbumin. Challenge
was subsequently performed intranasally or epicutaneously with ovalbumin and a secondary antigen, keyhole
limpet hemocyanin (KLH). Re-challenge consisted of local application of either antigen alone. Analysis of KLH-
speciﬁc antibody responses, KLH-speciﬁc cytokines, and local inﬂammation demonstrated tolerance induction
toward the secondary antigen in the skin, whereas in the lung priming had occurred. Flow-cytometric analysis
revealed increased numbers of regulatory T cells (Tregs), increased cytotoxic T lymphocyte antigen-4 (CTLA-4)
expression, and an enhanced suppressive capacity of Tregs from skin-draining lymph nodes when compared with
Tregs from the lung-draining lymph nodes. Furthermore, depletion of Tregs resulted in restoration of collateral
priming in the skin. These results demonstrate crucial local differences between the Treg function in the skin and
lung to repetitive antigen exposure, which can decisively inﬂuence the immune response toward new antigens.
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INTRODUCTION
Polysensitization is a clinical phenomenon where a person is
sensitized to more than one allergen family and has an
increased susceptibility to develop new allergies, which can
occur in the various organs involved with allergic disease
manifestations (Fasce et al., 2004; Ciprandi et al., 2008).
Polysensitization has been modeled in mice as a process
where ongoing airway inﬂammation facilitates priming to
secondary unrelated antigens, which has been termed
“collateral priming” (Eisenbarth et al., 2004; Hayashi et al.,
2005; Blumchen et al., 2006; Cadot et al., 2010; van Rijt
et al., 2011, 2012). Collateral priming depends on adaptive
immune responses and IL-4 (Dittrich et al., 2008), modulating
T cell, dendritic cell (Dittrich et al., 2008), and epithelial
cell function (Albrecht et al., 2012), and also occurs in
T helper type 1 (Th1) and Th17 polarized airway inﬂam-
mation (Albrecht et al., 2011). However, studies addressing
immunological mechanisms involved in polysensitiza-
tion in other organ systems, such as the skin or the gut, are
lacking.
In this current study, we compared collateral priming in a
mouse model of allergic skin inﬂammation with a model of
allergic lung inﬂammation. We could demonstrate that, in
contrast to an ongoing pulmonary inﬂammation, an ongoing
skin inﬂammation does not facilitate priming to a secondary,
unrelated antigen. We identiﬁed differences in Tregs from the
skin versus lung-draining lymph nodes (dLNs) and demon-
strated restoration of collateral priming by depletion of Tregs
prior to EC antigen contact. This pre-clinical data underline
the therapeutic potential of repetitive allergen “desensitiza-
tion” via the skin to induce tolerance.
RESULTS
Collateral priming for antigen-speciﬁc antibody responses
observed only in the lung collateral group
To determine sub-immunogenic doses of two antigens
(ovalbumin (OVA) and keyhole limpet hemocyanin (KLH)),
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we performed titration experiments as shown in Figure 1. For
KLH, a dose of 1 μg via the epicutaneous (EC) route proved
insufﬁcient to induce immunoglobulin secretion (Figure 1a)
and for intranasal (IN) application a dose of 5 μg or less was
sub-immunogenic (Figure 1c), whereas for OVA the sub-
immunogenic dose was from 0.25 μg EC (Figure 1b) and from
5 μg IN (Figure 1d). Similarly, we used these experiments to
gauge doses for a clear-cut positive response. We proceeded
to develop a skin collateral priming model to compare
collateral priming in the skin with an established lung
collateral priming model.
We chose an OVA IP sensitization model that allows for the
same route of primary sensitization in both organ systems. It
has previously been utilized to study collateral priming in the
lungs (Eisenbarth et al., 2004) and was adapted from
established skin models (Spergel et al., 1998; Herrick et al.,
2003) by us. KLH was chosen as the second antigen.
Accordingly, we designated the following study groups:
the O/O group (OVA upon primary and secondary local
challenge), the O+K/K group (OVA and KLH upon primary
local challenge and KLH alone upon re-challenge), and
the K/K group (KLH upon challenge and re-challenge)
(Figure 2a).
OVA-speciﬁc IgG1 and IgE were elevated in the serum of
all the groups, conﬁrming sensitization toward OVA as a
primary antigen (Figure 2b and c). We observed increased
KLH-speciﬁc IgG1 and IgE in the lung collateral priming
group (O+K/K), conﬁrming collateral priming toward
KLH in the lung group (Figure 2d and e). However, in
the skin collateral priming group (O+K/K), we could not
detect induction of either KLH-speciﬁc IgG1 or IgE,
demonstrating a lack of B-cell priming toward KLH in the
skin (Figure 2d and e).
To exclude antigen-dependent effects, we performed
consecutive cross-over experiments where KLH was utilized
as the primary antigen for IP sensitization and OVA was used
as the secondary antigen (Figure 2f and g). Similarly to what
we had previously observed, IN OVA administration at sub-
immunogenic doses led to increased OVA-speciﬁc IgG1 and
IgE in the collateral priming group (lung O+K/O), whereas EC
OVA administration at sub-immunogenic doses did not
induce OVA-speciﬁc IgG1 or IgE (skin O+K/O).
Collateral priming for antigen-speciﬁc T-cell cytokine secretion
observed only in the lung collateral priming group
Subsequently, we compared T-cell polarization toward KLH
by re-stimulating cells from dLNs with KLH.
Analysis of IL-4 secretion upon re-stimulation with OVA
conﬁrmed T-cell priming and polarization toward the primary
antigen OVA in the O/O and O+K/K groups (Figure 3a).
However, the detection of IL-13 (Figure 3b) and IFN-γ
(Figure 3c) secretion in all the groups may reﬂect induced
secretion of IL-13 in skin dLNs post epicutaneous contact with
an antigen (Herrick et al., 2003).
Upon re-stimulation with KLH, we observed signiﬁcantly
elevated levels of IL-4 and IL-13 in the lung collateral priming
group in comparison with all other groups. This conﬁrmed the
occurrence of collateral priming (Figure 3d and e, lung). In
contrast, we did not observe increased levels of the Th2
cytokines in the skin collateral priming group (O+K/K) when
compared with the other skin groups (O/O, K/K, Figure 3d
and e, skin). Secretion of the Th1 cytokine IFN-γ was not
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Figure 1. Titration of sub-immunogenic doses. Animals were sensitized as outlined in the materials and methods section and challenged epicutaneously
(EC) (a and b) or intranasally (IN) (c, d) with the indicated doses. Ovalbumin (OVA)- (b and d) and keyhole limpet hemocyanin (KLH)- (a and c) speciﬁc
IgG1 and IgE were determined in the sera of the mice by ELISA. n=3 animals per group. Representative study from n=5 studies for KLH and n=2 studies for
OVA. NS, not signiﬁcant.
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Figure 2. Antigen-speciﬁc antibody response directed toward the secondary antigen observed only in the lung collateral group. (a) Schematic overview
of collateral priming protocol. (b and c) Ovalbumin (OVA)-speciﬁc IgG1 and IgE. (d and e) keyhole limpet hemocyanin (KLH)-speciﬁc IgG1 and IgE levels
detected in the sera of the mice by ELISA. (f and g) OVA-speciﬁc IgG1 and IgE levels detected in the sera of mice that had undergone a cross-over
collateral priming treatment with KLH used as primary and OVA as secondary antigen (doses for cross-over experiment are indicated in the Materials
and Methods section); detection by ELISA; n=3 animals per group. ***Po0.001. Representative study from n= 2 to 5 studies. EC, epicutaneous; IN, intranasal;
IP, intraperitoneal.
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signiﬁcantly different between the groups (Figure 3f). In
aggregate, these results demonstrated a lack of KLH-speciﬁc
priming of T cells in the skin via collateral priming.
Local inﬂammation was not observed in the skin collateral
group
In the bronchoalveolar lavage (BAL) of the lung collateral
priming group (O+K/K), cell counts were signiﬁcantly
increased when compared with the negative control group
(K/K) but were similar to the positive control group (O/O;
Figure 4a). The BAL cellular inﬂux consisted mainly of
eosinophils, which were undetectable in the negative control
group (Figure 4b). In addition, the levels of monocytes,
lymphocytes, and neutrophils were increased in the two
groups (Supplementary Figure S1a–c online).
However, in the skin-positive control group (O/O) epider-
mal thickening, lymphocytic inﬂux in the dermis, and mast
cell staining were much more pronounced than in either the
collateral priming group (O+K/K) or the negative control
group (K/K; Figure 4d and e). With this, there was a
statistically signiﬁcant difference in the mast cell counts
(Figure 4c). Overall, these data conﬁrmed a lack of local
inﬂammation in the skin collateral priming group as
compared with the lung.
Increased proportion and numbers of Tregs observed in skin
dLNs
Several studies have highlighted a central role of Tregs in skin
inﬂammation (Ghoreishi et al., 2009; Rosenblum et al., 2011;
Gomez de et al., 2012; Lehtimaki et al., 2012). However, as
their role in the lack of collateral priming in the skin had not
been deﬁned, we decided to address this. For this purpose, we
stained for CD4+Foxp3+ cells (Tregs) in dLNs. Flow
cytometric analysis of the dLNs in the skin revealed that not
only repetitive exposure to the primary antigen OVA (i.e., O/
O and O+K/K groups) but also to the secondary antigen KLH
(i.e., K/K/group) resulted in signiﬁcantly increased Treg
numbers and percentages (Figure 5a and b, denoted by $).
However, in the lung, repetitive antigen contact elicited only
a signiﬁcantly increased Treg number in the O+K/K group
(Figure 5b, denoted by $). Strikingly, we always observed
signiﬁcantly higher Treg percentages and numbers in the
animals exposed EC as compared with the animals of the
respective group exposed IN (Figure 5a and b, denoted by #).
Regarding Treg percentages, this also held true for the
comparison between naive (− /− ) animals in the skin and
the lung groups (Figure 5a, denoted by #).
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Figure 3. Antigen-speciﬁc T-cell cytokine secretion directed toward the secondary antigen observed only in the lung collateral priming group. Detection of
antigen-speciﬁc IL-4, IL-13, and IFN-γ secretion in the supernatants of draining lymph node (dLN) cells by ELISA after ex vivo re-stimulation with ovalbumin
(OVA) (a–c) or keyhole limpet hemocyanin (KLH) (d–f) for 72 hours. Depicted are cultures of LN cells from individual mice with n=5 animals per group.
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Increased CTLA-4 expression in skin dLNs
Cytotoxic T lymphocyte antigen-4 (CTLA-4) has been
implicated in conferring Treg-mediated suppression (Sansom
and Walker, 2006). We measured CTLA-4 expression with
ﬂow cytometry by analysis of mean ﬂuorescence intensity of
CTLA-4 from dLNs. This revealed that CTLA-4 expression was
signiﬁcantly higher on skin dLN Tregs from both the collateral
priming group (O+K/K) and the animals that had under-
gone two OVA challenges (O/O), when compared with the
expressions in their respective lung groups (O+K/K O/O,
Figure 5c, denoted by #). Similarly to what we had observed
with FoxP3+ cell numbers in the lung groups, antigen
treatment did not increase CTLA-4 expression when com-
pared with naive controls (− /− ; Figure 5c, lung). In contrast,
the skin groups treated with the primary antigen OVA showed
signiﬁcantly increased CTLA-4 expression for both the
positive control (O/O) and the collateral priming group (O
+K/K), when compared with the naive controls (Figure 5c,
skin, denoted by $).
Tregs from skin dLNs display enhanced suppressive activity
We performed suppression assays to evaluate the suppressive
capacity of Tregs from the two organ systems’ dLNs. Sorted
Tregs from depletion of regulatory T cells (DEREG) mice (Lahl
et al., 2007) submitted to the lung or skin collateral priming
treatment protocols (Figure 2a) were co-cultured with labeled
CD4+ responder T cells (Tresp) induced to proliferate by plate-
bound CD3/CD28. Analysis of VP-450 dilution within the
Tresp population via ﬂow cytometry after 72 hours showed
that ~59% of Tresp had been induced to proliferate at this time
point (Figure 6a, left graph). Analyses of Tresp proliferation in
co-culture with Tregs revealed that both skin and lung dLN–
derived Tregs inhibited Tresp proliferation (Figure 6a, middle
and right graph). Of note, at the 8:1 ratio (Tresp:Tregs), this
inhibition was signiﬁcantly greater for Tregs from the skin
dLNs (~17% proliferation) versus Tregs from the lung dLNs
(~37% proliferation; Figure 6a, middle and right graph).
Taken together, these results demonstrate that skin dLN Tregs
are not only more numerous after antigen contact but also
confer more efﬁcient suppression of proliferation compared
with dLN Tregs isolated from the lungs.
Depletion of Tregs restores EC priming toward a secondary
antigen
We depleted Tregs from DEREG mice before the ﬁrst
challenge in our EC model (Figure 2a). Flow-cytometric
analysis of blood samples 48 hours after the ﬁrst EC antigen
contact demonstrated sufﬁcient depletion of Tregs (Figure 6d,
left panel), whereas analyses of blood samples 48 hours after
the second EC antigen contact demonstrated repopulation
with Tregs (Figure 6d, right panel). Comparison of immuno-
globulin secretion by diphtheria toxin-treated mice versus
phosphate-buffered saline (PBS)-treated controls after the
complete EC collateral priming protocol (Figure 2a) revealed
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a signiﬁcant secretion of KLH-speciﬁc IgG1 and IgE only in
the Treg depleted group (Figure 6e and f). These results
suggest that the presence of Tregs contributed to the lack of
collateral priming that we had observed in the EC model.
DISCUSSION
Our data suggest that an ongoing skin inﬂammation does not
facilitate priming to a secondary, unrelated antigen. Thus, our
results starkly contrast the previous ﬁndings observed in
models for allergic lung inﬂammation (Eisenbarth et al., 2004;
Hayashi et al., 2005; van Rijt et al., 2011) but are in line with
studies from Rosenblum et al. (2011). These had shown that,
upon expression of a self-antigen in the skin, regulatory T cells
could become activated, proliferate, and differentiate into
potent suppressors.
We cannot completely exclude that differences in the
doses of the antigens underlie the differences we observed,
given the knowledge on antigen- and dosage-dependency of
tolerance induction in the skin (Cavani, 2008). However, we
believe that our technique of careful titration allowed us to
select equivalent antigen doses for both antigens and
supported our approach to use different doses of the
antigens. Our cross-over experiments supported our view
that the lack of collateral priming in the skin is antigen
independent, with Treg numbers and their capacity being
affected differently by repetitive antigen exposure in the skin
versus lung.
It has been acknowledged for some time that Tregs have a
decisive role in the suppression of skin inﬂammation (Ramsdell
and Ziegler, 2014). Furthermore, in models of atopic dermatitis
(AD) and contact hypersensitivity, Lehtimaki et al. (2012)
showed that repetitive EC contact increases the number of
Tregs in the skin, and depletion of these cells aggravates the
AD and the contact hypersensitivity phenotype (Fyhrquist et al.,
2012). These results are in accordance with our own ﬁndings.
Furthermore, depletion of Tregs during the sensitization phase
can aggravate allergic airway inﬂammation (Baru et al., 2010),
whereas depletion during the challenge phase has no such
effect (Baru et al., 2012). Similarly, we could retrace these
ﬁndings in our own depletion experiments: immunoglobulin
responses toward the primary antigen (OVA) were not
inﬂuenced by depletion of Tregs during the challenge phase
(Supplementary Figure S3 online), but depletion of Tregs during
EC sensitization with the secondary antigen allowed collateral
priming to take place in the skin. In addition, our own data
provide a comparison of the ex vivo suppressive capacities of
the skin versus lung Tregs from the collateral priming groups (O
+K/K, Figure 6a–c). Our data suggest that the functional
differences we observed might be attributable to differences
in CTLA-4 expression (Figure 5c, denoted by #) and also
quantitative differences of Tregs (Figure 5a and b,
denoted by #).
Different mechanisms might lead to the qualitative and
quantitative differences between Tregs in the skin and lung. In
steady-state human peripheral blood, the majority of Tregs
express CLA, a skin homing receptor (Hirahara et al., 2006).
This suggests that skin homing of Tregs constitutes a preferred
route of Treg trafﬁcking under steady-state conditions, thereby
facilitating tolerance induction via the skin. In addition, skin
inﬂammation has been shown to increase LN-directed Treg
homing (Tomura et al., 2010) and triggers reverse circulation
of Tregs from LNs to the skin (Matsushima and Takashima,
2010). This mechanism could contribute to the loss of
epicutaneous priming against KLH. In this context, our
ﬁndings that repetitive antigen contact increases Treg
percentages and numbers in the skin (Figure 5a and b,
denoted by $) but fails to do the same in the lung would
support this hypothesis. Single contact with the secondary
antigen was not sufﬁcient to increase Treg percentages or
numbers, suggesting that the repetition of the treatment
played a decisive role for tolerance induction in the skin
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(Figure 5a and b, K only group: -/K). Our experimental groups,
however, cannot clarify whether Treg recruitment to the skin
is driven by repetitive antigen contact or the effects of
patching alone, as we did not include a “patch only” group
without antigen.
The composition and function of antigen-presenting cells
differ considerably between the lung and the skin (Liu and
Nussenzweig, 2010; Igyarto et al., 2011). For example,
dermis-derived CD103− dendritic cells have been shown to
induce Tregs (Guilliams et al., 2010). Furthermore, Langerhans
cells induce tolerance in a contact hypersensitivity model
(Gomez de et al., 2012) and have no counterpart in the lungs.
On the other hand, persistent activation of airway dendritic
cells in the lungs during the “post inﬂammatory stage” has
been implicated in polysensitization (van Rijt et al., 2011). It
seems conceivable that differences in antigen-presenting cell
composition and function confer the striking differences we
observed in terms of secondary (poly-) sensitization, an issue
we will need to address in future studies.
Our results do not concur with the clinical observation that
polysensitization also occurs in patients with AD (Ciprandi
et al., 2008). Two major differences in pathophysiology might
underlie the discrepancy between clinical observations and
our data: (i) skin barrier dysfunction has an important role in
the development of AD (Oyoshi et al., 2010; De et al., 2012),
whereas tolerance induction through administration of an
antigen via the EC route crucially depends upon an intact skin
barrier (Mondoulet et al., 2012). (ii) Skin lesions of an AD
individual are typically colonized with Staphylococcus
aureus (Breuer et al., 2000, 2002). Disruption of skin barrier
function and addition of staphylococcal super-antigens could
lead to a skin milieu more conducive to sensitization in our
model, which we need to test in further studies.
Epicutaneous immunotherapy with allergen has been
demonstrated as being a potential alternative, needle-free,
and self-administrable treatment route for subcutaneous
immunotherapy in both animal and human studies (reviewed
in Senti et al. (2014)). Our ﬁndings contribute to this
therapeutic application by demonstrating that skin Tregs
increase with repetitive EC antigen exposure and,
furthermore, that there are functional differences between
skin and lung Tregs after repetitive local antigen exposure.
Similar to Dioszeghy et al. (2014), we showed that depletion
of Tregs restores sensitization, conﬁrming their crucial role for
tolerance induction in the skin. These ﬁndings promote the
concept of epicutaneous immunotherapy with allergen and
suggest that repetitive EC contact leads to local induction of
Tregs, which can prevent sensitization toward new allergens
through their potent suppressive capacity. Our data could
provide an important basis for superior ﬁne tuning of
epicutaneous immunotherapy with allergen-containing thera-
pies, with an aim of improving the Treg induction and
suppressive capacity, and to potentially prevent polysensiti-
zation in mono-sensitized patients.
MATERIALS AND METHODS
Animals
Six- to eight-week-old female BALB/c mice were purchased from
Charles River Laboratory (Charles River, Lengefeld, Germany).
DEREG (depletion of regulatory T cells) mice (Tg(Foxp3-DTR/EGFP)
23.2Spar; Lahl et al., 2007) on BALB/c mice background were bred
in-house. All experimental procedures were performed according to
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Figure 6. Skin regulatory T cells (Tregs) confer enhanced suppression compared with lung Tregs, and their depletion restores collateral priming in the skin.
(a) Representative cytometric analyses suppression assay. responder T cells (Tresp) alone (left), in co-culture with lung-draining lymph nodes (dLNs) Tregs
(middle) or skin dLN Tregs (right) at a ratio of 8:1 Tresp:Tregs for 72 hours. (b and c) Percentage of suppression and proliferation of Tresp co-cultured with
lung versus skin dLN Tregs at different ratios for 72 hours. + denotes Only Tresp Tregs, − denotes Tresp not stimulated. Representative experiment from n=3.
(d) Depletion and repopulation control of Tregs in blood samples by ﬂow cytometry (CD4+GFP+Foxp3+) of diphtheria toxin (DTX)- and non-treated depletion
of regulatory T cells (DEREG) mice. (e and f) Depletion of Tregs during ﬁrst patch restores keyhole limpet hemocyanin (KLH)-speciﬁc IgG1 and KLH-speciﬁc IgE
responses in sera. n=5 animals per group. −/−: PBS patch. *P40.05 and **P40.01.
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the local guidelines of the animal welfare law, Landesamt für
Verbraucherschutz und Lebensmittelsicherheit (protocol 09-1664).
Titration of sub-immunogenic doses
Naive BALB/c mice were sensitized IP on day 0 and day 7: 20 μg of
OVA (grade V; Sigma-Aldrich, Munich, Germany) or KLH
(with 1.5 mg alum; Sigma-Aldrich), with negative control groups
receiving alum in PBS. In the skin groups, mice were challenged by
EC patches from day 18 to 22 and from day 38 to 42 with the
help of a circular water proof band-aid (23mm; Hansaplast,
Beiersdorf, Germany) in the indicated doses (Figure 1a and b).
The band-aid was placed on the shaved back skin and glued
with the help of an adhesive (Mastisol, Eloquest Healthcare,
Ferndale, MI). In the lung groups, mice were challenged IN on day
18, 19, and 20 and re-challenged on day 35, 36, 39, and 40 with the
indicated doses (Figure1c and d). Killing was performed on day 42 for
both groups.
Collateral priming protocol
Priming and challenge were performed as outlined above, with the
doses as shown in Figure 2a. The positive groups (O/O) received
OVA in both challenges; the collateral priming (O+K/K) groups
received OVA and KLH (Sigma-Aldrich) in the ﬁrst and KLH in the
second challenge.
Sub-inﬂammatory doses (i.e., doses not leading to primary
sensitization) and challenge doses had been titrated for each organ
system in previous experiments (Figure 1) and are indicated in
Figure 2a. All mice were killed and analyzed on day 42 (Figure 1).
For cross-over experiments sensitization, challenges, and euthanasia
were performed as shown in Figure 2a with the following antigen
doses: IP sensitization: 20 μg of KLH (Sigma-Aldrich); challenges:
lung group: KLH 25 μg+OVA 5 μg (grade V; Sigma-Aldrich) for the
ﬁrst challenge, followed by OVA 25 μg for second challenge; skin
group: KLH 100 μg+OVA 0.25 μg for the ﬁrst challenge, followed
by OVA 100 μg for the second challenge.
In the depletion experiment, DEREG mice were submitted
to the EC collateral priming group protocol (Figure 2a, negative
controls receiving PBS patches), with 25 μg kg−1 bodyweight
IP injection of diphtheria toxin 24 hours before and after ﬁrst patch
application.
Analysis of BAL ﬂuid
BAL inﬂammatory cells were obtained and analyzed as described
previously (Dittrich et al., 2008).
Skin histology
Parafﬁn-embedded skin samples were sectioned (5 μm), stained
with hematoxylin and eosin or toluidine blue, and photographs
obtained at × 200 using an Olympus BX51 microscope
(Olympus, Hamburg, Germany). For mast cell counts, 35 high-
power ﬁelds from 7 different sections per group were counted in a
blinded manner.
Determination of serum antibody concentration
Antigen-speciﬁc antibodies in sera were determined by means of
ELISA, as described previously (Dittrich et al., 2008).
Lymph node re-stimulation assays
Single-cell suspensions from dLNs (mediastinal and axillary) of
individual mice were re-stimulated for cytokine secretion as
described previously (Dittrich et al., 2008).
Cytokine ELISA
Cytokines levels of IFN-γ, IL-4, and IL-13 in culture supernatants
were determined by means of ELISA DuoSet kits (R&D Systems,
Wiesbaden-Nordenstadt, Germany) according to the manufacturer’s
instructions.
Flow-cytometric analysis
Cells were stained on ice for surface markers with ﬂuorescently
labeled antibodies (α-CD4 (clone RM4-5), α-CD3 (clone 145-2C11,
all BD Biosciences, Heidelberg, Germany)) after blocking with anti-
FcR (clone 24G2, lab grown) antibody. Consecutively, cells were
ﬁxed and permeabilized with the eBioscience Fix and Perm kit
(Frankfurt, Germany) according to the manufacturer’s protocols.
Labeling with ﬂuorescently coupled antibodies was then performed
(α-Foxp3 (clone FJK-16s), α-CTLA-4 (clone UC10-4F10-11, all
eBioscience, Frankfurt, Germany)). Cells were analyzed on a LSRII
(BD Biosciences) ﬂow cytometer in association with FlowJo (Treestar,
Ashland, OR) software.
Suppression assay
Overall, 96-well round bottom plates were coated with antibodies
overnight at 37°C (α-CD3 (clone 2C11), α-CD28 (clone 37.51, both
lab grown)). Prior to seeding cells, plates were washed with sterile
PBS. Splenic CD4+ T cells (Tresp) were isolated as described
previously (Dittrich et al., 2008) and labeled with VPD450 dye (BD
Biosciences) according to the manufacturer’s instructions. Tresp were
co-cultured with CD4+GFP+ cells sorted on a FacsAria from
mediastinal or axillary LNs of 10–15 DEREG mice, which had been
submitted to the treatment protocol for the EC or IN collateral priming
group. Purity of the sorted CD4+GFP+ cells was assessed by means
of ﬂow cytometry (Supplementary Figure S2 online). Ratios of Tresp to
GFP+/Tregs were as indicated, 1 being 4× 104 cells. Culture
conditions were set up in triplicates. Analysis of T-cell proliferation
via ﬂow-cytometric dilution of VPD450 dye was performed on
day 3. Percentage of suppression was calculated as follows:
100− [100× (percentage of proliferation of sample/percentage of
proliferation of positive control)].
Statistical analysis
For statistical analysis, t-tests or one way analysis of variance in
conjunction with Bonferroni’s multiple comparison tests was
performed with the GraphPad Prism software (Graph Pad Software,
La Jolla, CA) to determine statistical differences between means or
proportions between two groups of data.
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